Bladder cancer
Conditions
Interventions
Gold Standard:Urine routine examination, imaging, pathological results of urine exfoliated cells and urine FISH results
Index test:Urine DNA methylation
Sponsors
Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Judge the case group of tumor residue: (1) Patients with previously diagnosed high-risk NMIBC are proposed to undergo secondary TURBT; (2) Age >= 18 years old, regardless of gender; (3) The interval between the last infusion of chemotherapeutic drugs or immunotherapeutic drugs is 1 week or more; (4) It can provide 100ml morning urine sample before treatment while receiving routine treatment; (5) Tumor residue was confirmed by TURBT operation and pathology. 2. Control group for judging tumor residue: (1) Patients with previously diagnosed high-risk NMIBC are proposed to undergo secondary TURBT; (2) Age >= 18 years old, regardless of gender; (3) The interval between the last infusion of chemotherapeutic drugs or immunotherapeutic drugs is 1 week or more; (4) It can provide 100ml morning urine sample before treatment while receiving routine treatment; (5) No residual tumor was diagnosed by TURBT. 3. Case group for judging tumor recurrence (1) Patients with previously diagnosed NMIBC after TURBT are planned to undergo follow-up cystoscopy; (2) Age >= 18 years old, regardless of gender; (3) The interval between the last infusion of chemotherapeutic drugs or immunotherapeutic drugs is 1 week or more; (4) It can provide 100ml morning urine sample before treatment while receiving routine treatment; (5) The tumor recurrence was confirmed by cystoscopy and biopsy pathology. 4. Judgment of tumor recurrence in control group: (1) Patients with previously diagnosed NMIBC after TURBT are planned to undergo follow-up cystoscopy; (2) Age >= 18 years old, regardless of gender; (3) The interval between the last infusion of chemotherapeutic drugs or immunotherapeutic drugs is 1 week or more; (4) It can provide 100ml morning urine sample before treatment while receiving routine treatment; (5) No tumor recurrence was confirmed by cystoscopy and biopsy.
Exclusion criteria
Exclusion criteria: NA
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Urine DNA methylation; | — |
Countries
China
Contacts
Public ContactChen Xu
Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University
Outcome results
None listed